ArticleBriefings in bioinformatics2026
HighRes_Builder: improved access and modeling of noncanonical residues for protein structure prediction.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The growing support for noncanonical amino acids in structure prediction tools such as AlphaFold3 has been largely facilitated by the Chemical Component Dictionary (CCD). However, the limited coverage of modified residues in CCD continues to restrict the application of these models to many biologically and therapeutically relevant peptides. To address this gap, we present HighRes_Builder, a computational method for efficient residue search and automated construction of noncanonical amino acids not currently archived in CCD. We demonstrate the utility of our approach by predicting structures for 3179 noncanonical residues beyond the CCD using AlphaFold3. AlphaFold3 achieved 100% acceptance for both the noncanonical residue monomers and their corresponding 'GGXGG' motifs (where X denotes the noncanonical residue). Of these, 72.44% of the predicted residue monomer structures concurrently satisfy all five geometric criteria (d_N_C1, d_Ck_Ccarb, d_Ccarb_O_mean, ang_Ck_Ccarb_O_mean, and ang_O1_Ccarb_O2). Furthermore, among the generated motif structures, 85.78% exhibited favorable ω values for the embedded noncanonical residues. Furthermore, by integrating HighRes_Builder with structure prediction systems, AlphaFold3 for linear peptides and HighFold3 for cyclic peptides, we successfully model the conformation of the linear peptide drug Relamorelin and the cyclic therapeutic peptides LUNA18 and JNJ-77242113 in complex with their target proteins, elucidating structural determinants of their mechanism of action. This work establishes a scalable and accurate framework for structure prediction of diverse nonstandard peptides, highlighting its potential to accelerate rational design of peptide-based therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.